GeNeuro SA (GNRRF)
- Business Wire
GeNeuro: Financial Information and Business Update for the Second Quarter 2022
GENEVA, July 21, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.
- Business Wire
GeNeuro: Study Confirming the Key Role of Human Endogenous Retroviruses (HERV-K) for ALS Published in "Annals of Neurology", a Leading Scientific Journal
GENEVA, July 20, 2022--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today the publication in the leading scientific journal "Annals of Neurology" of the results of the collaboration between GeNeuro and the National Ins
- Business Wire
GeNeuro Will Contribute Its Expertise in Human Endogenous Retroviruses to the €6.8M EU-Funded HERVCOV Precision Medicine Project
GENEVA & LYON, France, June 20, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), announces today that its R&D subsidiary GeNeuro Innovation SAS will be the industrial R&D partner of the HERVCOV project funded with a €6.8 million grant from
